Perspectives and Insights From MF experts
The resources on this page offer information and insights about Jakafi® (ruxolitinib) and treatment of patients with intermediate- or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF, and post–essential thrombocytopenia MF. Be sure to check back regularly as new materials will be added as they become available.
Dr Mesa’s Perspective:
Spleen Volume Reduction and Long-Term Survival in MF
Dr Mesa’s Perspective:
Spleen Volume Reduction and
Long-Term Survival in MF
Hematologist-oncologist Dr Ruben Mesa shares how he uses Jakafi to actively manage his patients with MF who have splenomegaly and discusses how intervening at diagnosis may impact spleen volume and overall survival.
Dr Mesa’s Perspective:
Managing Anemia in Patients With MF
Dr Mesa’s Perspective:
Managing Anemia in Patients With MF
Hematologist-oncologist Dr Ruben Mesa discusses the importance of intervening with Jakafi regardless of anemia status and his approach to managing baseline and new-onset anemia during treatment.
Dr Fazal’s Perspective:
Intervening Early in MF
Dr Fazal’s Perspective:
Intervening Early in MF
Hematologist and bone marrow transplant physician Dr Salman Fazal shares why he intervenes with Jakafi at diagnosis for his patients with intermediate-1–, intermediate-2–, or high-risk MF.
Dr Fazal’s Perspective:
Spleen and Overall Survival in MF
Dr Fazal’s Perspective:
Spleen and Overall Survival in MF
Hematologist and bone marrow transplant physician Dr Salman Fazal explains why the data for Jakafi give him the confidence to prescribe treatment at diagnosis for his appropriate patients.
Dr Fazal’s Perspective:
Considering Anemia in MF
Dr Fazal’s Perspective:
Considering Anemia in MF
Hematologist and bone marrow transplant physician Dr Salman Fazal explains why disease-related anemia may not be a reason to delay treatment with Jakafi.
